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Endovascular Treatment of Acute Ischemic Stroke
With the Penumbra System in Routine Practice
COMPLETE Registry Results
Osama O. Zaidat , MD, MS; Johanna T. Fifi , MD; Ashish Nanda, MD; Benjamin Atchie , DO; Keith Woodward, MD;
Arnd Doerfler , MD, PhD; Alejandro Tomasello , MD; Wondwossen Tekle , MD; Inder Paul Singh, MD;
Charles Matouk , MD; Jörg Thalwitzer , MD, PhD; Tomasz Jargiełło, MD, PhD; Dmitry Skrypnik , MD, PhD;
Oliver Beuing , MD; Jérôme Berge , MD; Jeffrey M. Katz , MD; Alessandra Biondi , MD, PhD; David Bonovich, MD;
Sunil A. Sheth , MD; Albert J. Yoo , MD, PhD; Ameer E. Hassan , DO; on behalf of the COMPLETE Registry Investigators*
BACKGROUND AND PURPOSE: The purpose of the COMPLETE (International Acute Ischemic Stroke Registry With the Penumbra
System Aspiration Including the 3D Revascularization Device) registry was to evaluate the generalizability of the safety and
efficacy of the Penumbra System (Penumbra, Inc, Alameda) in a real-world setting.
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METHODS: COMPLETE was a global, prospective, postmarket, multicenter registry. Patients with large vessel occlusion–
acute ischemic stroke who underwent mechanical thrombectomy using the Penumbra System with or without the 3D
Revascularization Device as frontline approach were enrolled at 42 centers (29 United States, 13 Europe) from July
2018 to October 2019. Primary efficacy end points were successful postprocedure angiographic revascularization
(modified Thrombolysis in Cerebral Infarction ≥2b) and 90-day functional outcome (modified Rankin Scale score 0–2).
The primary safety end point was 90-day all-cause mortality. An imaging core lab determined modified Thrombolysis
in Cerebral Infarction scores, Alberta Stroke Program Early CT Scores, clot location, and occurrence of intracranial
hemorrhage at 24 hours. Independent medical reviewers adjudicated safety end points.
RESULTS: Six hundred fifty patients were enrolled (median age 70 years, 54.0% female, 49.2% given intravenous recombinant
tissue-type plasminogen activator before thrombectomy). Rate of modified Thrombolysis in Cerebral Infarction 2b to 3
postprocedure was 87.8% (95% CI, 85.3%–90.4%). First pass and postprocedure rates of modified Thrombolysis in Cerebral
Infarction 2c to 3 were 41.5% and 66.2%, respectively. At 90 days, 55.8% (95% CI, 51.9%–59.7%) had modified Rankin
Scale score 0 to 2, and all-cause mortality was 15.5% (95% CI, 12.8%–18.3%).
CONCLUSIONS: Using Penumbra System for frontline mechanical thrombectomy treatment of patients with large vessel
occlusion–acute ischemic stroke in a real-world setting was associated with angiographic, clinical, and safety outcomes that
were comparable to prior randomized clinical trials with stringent site and operator selection criteria.
REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT03464565.
GRAPHIC ABSTRACT: A graphic abstract is available for this article.
Key Words: cerebral infarction ◼ ischemic stroke ◼ mortality ◼ reperfusion ◼ thrombectomy
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*A table listing all investigators who participated in the COMPLETE registry is available in the Data Supplement.
The Data Supplement is available with this article at https://www.ahajournals.org/doi/suppl/10.1161/STROKEAHA.121.034268.
For Sources of Funding and Disclosures, see page 777.
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Nonstandard Abbreviations and Acronyms
AIS
acute ischemic stroke
ASPECTS	Alberta Stroke Program Early CT
Score
ECASS	European Cooperative Acute Stroke
Study
ENT	Embolization in previously uninvolved
or New Territories
LVO
large vessel occlusion
mRS
modified Rankin Scale
MT
mechanical thrombectomy
mTICI	modified Thrombolysis in Cerebral
Infarction
SAE
serious adverse event
sICH
symptomatic intracranial hemorrhage

Results of the COMPLETE Registry

thrombectomy as noninferior to stent retrievers.2 These
trials had strict site selection criteria, enrollment criteria,
and restricted patient population by anterior circulation
LVO location,13,14,16 time from symptom onset,13–16 and
eligibility-for or response-to intravenous thrombolytic
therapy.15 Furthermore, several recent additions to the
Penumbra System were not included in these prior trials.
This study, the COMPLETE (International Acute Ischemic Stroke Registry With the Penumbra System Aspiration Including the 3D Revascularization Device) Registry,
evaluated the generalizability of the Penumbra System’s
performance in a real-world setting.

METHODS

echanical thrombectomy (MT) is the current
standard of care for large vessel occlusion–
acute ischemic stroke (LVO-AIS) treatment.1,2
Results from multiple randomized controlled trials
support the safety and efficacy of MT.3–8 This may be
related to improved patient selection and newer generation thrombectomy devices.
The American Heart/American Stroke Association
2019 and the European Stroke Organization/European
Society for Minimally Invasive Neurological Therapy
2019 Guidelines agree that high-quality evidence exists
to support the use of MT plus best medical management
over best medical management alone in patients with
anterior circulation LVO-AIS with an Alberta Stroke Program Early CT Score (ASPECTS) ≥6 presenting within
6 hours of onset. Both also agree that MT is reasonable
and should be considered for patients with ASPECTS<6,
or posterior circulation occlusions, but acknowledge the
lack of high-quality evidence available for these less
explored populations.1,2
The Penumbra System (Penumbra Inc, Alameda) is
an MT system specifically designed to remove thrombus
using aspiration.9–11 Several design and catheter size
iterations have been made since the initial commercial
launch and the Penumbra System was used in several
trials, including ADAPT FAST (A Direct Aspiration First
Pass Technique for Acute Stroke Thrombectomy),12
ASTER (The Contact Aspiration vs Stent Retriever for
Successful Revascularization),13 PROMISE (Prospective Multicenter Imaging Study for Evaluation of Chest
Pain),14 the 3-dimensional (3D) Randomized Trial,15 and
COMPASS (Cardiovascular Outcomes for People Using
Anticoagulation Strategies)16—providing additional clinical data supporting the Penumbra System’s performance.
Citing results of COMPASS,16 ASTER,13 and the 3D Randomized Trial,15 the American Heart/American Stroke
Association guidelines endorse frontline aspiration

COMPLETE was a global, prospective, multicenter, single-arm,
postmarket, registry assessing the performance of the Penumbra
System in an LVO-AIS patient population. Forty-two sites (29
United States, 13 Europe) enrolled patients from July 2018
through October 2019, and 90-day follow-up was completed in
January 2020. The data that support the findings of this study are
available from the corresponding author upon reasonable request.
Inclusion criteria were patient age ≥18 years, prestroke
modified Rankin Scale (mRS) score 0 to 1, patient experiencing
AIS secondary to intracranial LVO who is eligible for MT using
Penumbra System, planned frontline treatment with Penumbra
System, and signed informed consent per Institutional Review
Board/Ethics Committee.
Exclusion criteria were any comorbid disease or condition
expected to compromise survival or ability to complete follow-up
assessments through 90 days and currently participating in an
investigational (drug, device, etc) clinical trial that will confound
registry end points. Patients in observational, natural history, or epidemiological studies not involving intervention remained eligible.
Investigators used routine clinical evaluations to determine
patient eligibility. Advanced imaging was not required but permissible per site standard of care. A screening and enrollment log of
all MT eligible patients with LVO-AIS was maintained at each participating hospital with reason(s) for exclusion recorded. Patients
were considered enrolled once informed consent was obtained
and Penumbra System was inserted into the body. Participating
hospitals entered data into the Oracle InForm electronic data
capture system (Oracle, Austin, TX). To ensure data accuracy and
protocol compliance, the sponsor implemented risk-based monitoring. The RECORD (Reporting of Studies Conducted Using
Observational Routinely-Collected Data) statement checklist and
study flow diagram are available in the Data Supplement.17
Frontline treatment modality (direct aspiration only or aspiration combined with a 3D Revascularization Device) was decided
by the treating physician. Procedures were conducted in accordance with routine care. Available devices included the MAX,
ACE, and JET reperfusion catheters; the 3D Revascularization
Device; and the Pump MAX, and ENGINE aspiration sources.
The catheter distal inner dimensions ranged from 0.035” (0.89
mm) to 0.072” (1.83 mm). The aspiration sources are designed
to deliver and maintain a consistent vacuum (−29.2 in Hg or
98.9 kPa for ENGINE).
The following predefined cohorts represent different
patient populations and were reported separately: cohort A
(anterior LVO with ASPECTS≥6), cohort B (anterior LVO with
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End Points
The primary efficacy end points were angiographic revascularization of the occluded target vessel at immediate postprocedure as defined by modified Thrombolysis in Cerebral Infarction
(mTICI) score ≥2b and functional subject outcome at 90 days
postprocedure defined as mRS score 0 to 2. mTICI 2b was
defined as substantial reperfusion with distal branch filling of
≥50% of territory visualized. The primary safety end point was
all-cause mortality at 90 days.
The secondary end points included incidence of device- and
procedure-related serious adverse events (SAEs), occurrence
of embolization in previously uninvolved or new territories (ENT)
as seen on the final control angiogram at the end of procedure,
occurrence of symptomatic intracranial hemorrhage (sICH) at
24 hours, and time to revascularization.
Efforts were made to reduce the number of patients lost
to follow-up. At a minimum, this included 3 attempts to make
contact via telephone or email, and if unsuccessful, a letter from
the investigator was sent via certified mail or other traceable
methods to the patient’s last known address. Patients were
considered lost to follow-up if these efforts failed. Assessments
of mRS were performed per site standard of care. Other end
point information is presented based on imaging core lab or
independent medical reviewer assessments.

Downloaded from http://ahajournals.org by on April 11, 2022

Study Committees
An independent imaging core lab reviewed pseudonymized angiography for mTICI scores, preprocedure CT for ASPECTS, computed tomography angiography for clot location, and 24-hour CT
to assess hemorrhagic transformation using ECASS (European
Cooperative Acute Stroke Study) classification.
Independent medical reviewers adjudicated all devicerelated SAEs, neurovascular procedure–related SAEs, sICH
within 24 hours, events of neurological deterioration, and any
deaths that occurred throughout the registry. Neurological deterioration was defined as a ≥4-point worsening of the National
Institutes of Health Stroke Scale score from baseline, and sICH
was defined as 24-hour evidence of an ECASS defined ICH
associated with a ≥4-point worsening of the National Institutes
of Health Stroke Scale score from baseline.

could be obtained within 2 calendar days. In Europe, informed
consent was obtained for all cases before the procedure from
the patient, next of kin, legally authorized representative, or 1
or 2 independent physician(s); if informed consent could not
be obtained directly from the patient before procedure, it was
obtained again before discharge either from the patient or other
authorized persons per local Ethics Committee requirements.

Statistical Analysis
Data were summarized using standard descriptive statistics
(number of observations, mean, median, SD, and interquartile
range for continuous variables, and counts and percentages
for discrete variables). Statistical tests for continuous variables
used the Wilcoxon Mann-Whitney rank-sum test and categorical variables were tested using Fisher exact test. Two-sided
Exact Clopper-Pearson CI are presented. All statistical tests
are 2-tailed with a significance level of 0.05. Sensitivity analyses were done using 3 imputation strategies for patients with
missing primary efficacy end point data: poor outcome (mRS
score 3–6), good outcome (mRS score 0–2), and multiple
imputation. Poolability analysis with a hierarchical linear mixed
model accounting for patient characteristics was performed.
See Data Supplement for additional details. Analyses were
conducted using SAS (SAS Institute, Cary, NC).
An estimated sample size of 650 was chosen for its ability to provide a sufficient level of precision to assess the
Penumbra System and 3D Revascularization Device in the prespecified primary cohort A based on previously reported incidence rates. Approximately 500 patients (≈77% of enrollment)
were anticipated to be in cohort A. Assuming a postprocedure
angiographic success rate of 85% (425/500), the expected
binomial 2-sided 95% CI was (81.9%–88.1%). Assuming 10%
attrition and a 90-day mRS success rate of 45% (202/450),
the expected binomial 2-sided 95% CI was (40.3%–49.5%).
Approximately 100 patients (≈15% of enrollment) were
anticipated to be in cohort B, and ≈50 patients (≈8% of enrollment) were anticipated to be in cohort C.

RESULTS

The study and informed consent process were approved by the
Institutional Review Board/Ethics Committee for each participating center before registry initiation. Informed consent was
obtained for all enrolled patients per local Institutional Review
Board/Ethics Committee requirements. See Data Supplement
for a complete list of all Institutional Review Board/Ethics
Committee. The informed consent process was consistent
with the applicable elements of EN ISO14155, clinical investigation of medical devices for human subjects—good clinical
practice and 21 Code of Federal Regulations Part 50 and 54.
In the United States, for emergent cases where the patient
was unable to provide consent and a legally authorized representative was absent before the procedure, informed consent

Of the 1501 patients screened, 650 were enrolled (454
United States, 196 Europe). A study flow diagram and
screen failure details are available in the Data Supplement. The completion rate through final follow-up was
high (94.6%), and the attrition rate (5.4%) was better
than the expected 10%. Of the 35 patients that did not
complete the study, 5 withdrew consent, 2 were withdrawn by a study investigator, 25 were lost to follow-up,
and 3 did not complete for other reasons.
Baseline data are presented in Table 1. Median age
was 70 years (range, 22–96 years), and 54% were
female. Most patients (52.8%) were transferred from
another hospital, and 49.2% received intravenous
recombinant tissue-type plasminogen activator before
thrombectomy. Strokes were witnessed, wakeup, or
unwitnessed in 52.2%, 10.0%, and 37.8% of cases,
respectively. Median time from onset to door was 193
minutes (interquartile range, 83–378), and median time
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Table 1. Baseline Characteristics and Procedural Data
All subjects (N=650)

Cohort A/anterior circulation ASPECTS≥6 (n=525)

Cohort B/anterior circulation ASPECTS<6 (n=72)

Cohort C/posterior
circulation (n=51)

Female

54.0% (351/650)

56.8% (298/525)

44.4% (32/72)

39.2% (20/51)

Age, y

70.0 [60.0–79.0]

71.0 [61.0–80.0]

66.0 [53.0–76.5]

66.0 [57.0–80.0]

  Asian

2.9% (13/454)

2.5% (9/363)

3.8% (2/53)

5.4% (2/37)

  Black

13.4% (61/454)

12.7% (46/363)

13.2% (7/53)

18.9% (7/37)

  White

79.5% (361/454)

80.7% (293/363)

77.4% (41/53)

73.0% (27/37)

  Other

1.3% (6/454)

1.1% (4/363)

3.8% (2/53)

0.0% (0/37)

  Not reported

2.9% (13/454)

3.0% (11/363)

1.9% (1/53)

2.7% (1/37)

   Previous ischemic stroke

14.9% (97/650)

15.0% (79/525)

13.9% (10/72)

15.7% (8/51)

   Previous hemorrhagic stroke

0.3% (2/650)

0.4% (2/525)

0.0% (0/72)

0.0% (0/51)

  Atrial fibrillation

33.4% (217/650)

35.4% (186/525)

19.4% (14/72)

31.4% (16/51)

  Cardiovascular/vascular disease

50.8% (330/650)

51.4% (270/525)

47.2% (34/72)

49.0% (25/51)

  Diabetes

23.7% (154/650)

23.0% (121/525)

22.2% (16/72)

31.4% (16/51)

  Hypertension

72.0% (468/650)

72.4% (380/525)

65.3% (47/72)

76.5% (39/51)

  Hyperlipidemia

42.3% (275/650)

42.1% (221/525)

41.7% (30/72)

45.1% (23/51)

  Renal failure

5.5% (36/650)

5.5% (29/525)

4.2% (3/72)

7.8% (4/51)

0.6% (4/650)

0.8% (4/525)

0.0% (0/72)

0.0% (0/51)

Initial NIHSS

15.0 [9.0–20.0] (n=648)

14.0 [9.0–20.0] (n=524)

18.0 [15.5–22.0] (n=72)

12.0 [5.0–18.0] (n=50)

Initial ASPECTS

8.0 [7.0–9.0] (n=597)

8.0 [7.0–9.0] (n=525)

4.0 [3.0–5.0] (n=72)

N/A

Initial pc-ASPECTS

9.0 [8.0–10.0] (n=49)

N/A

N/A

9.0 [8.0–10.0] (n=49)

  ICA

4.6% (30/650)

5.3% (28/525)

2.8% (2/72)

N/A

  ICA-T

12.8% (83/650)

11.8% (62/525)

29.2% (21/72)

N/A

  ACA

0.6% (4/650)

0.6% (3/525)

0.0% (0/72)

N/A

  MCA, M1

55.2% (359/650)

59.8% (314/525)

62.5% (45/72)

N/A

  MCA, M2

17.4% (113/650)

20.6% (108/525)

5.6% (4/72)

N/A

  MCA, M3

1.4% (9/650)

1.7% (9/525)

0.0% (0/72)

N/A

  MCA, M4

0.2% (1/650)

0.2% (1/525)

0.0% (0/72)

N/A

  Vertebral

0.2% (1/650)

N/A

N/A

2.0% (1/51)

  Basilar, proximal

0.8% (5/650)

N/A

N/A

9.8% (5/51)

  Basilar, mid

1.4% (9/650)

N/A

N/A

17.6% (9/51)

  Basilar, terminus

2.9% (19/650)

N/A

N/A

37.3% (19/51)

  PCA

2.5% (16/650)

N/A

N/A

31.4% (16/51)

Other, both PCA and proximal SCA

0.2% (1/650)

N/A

N/A

2.0% (1/51)

Transferred from another hospital

52.8% (343/650)

51.8% (272/525)

58.3% (42/72)

56.9% (29/51)

IV r-tPA administered

49.2% (320/650)

50.1% (263/525)

58.3% (42/72)

29.4% (15/51)

Baseline demographics

Race*

Past medical history

Prestroke mRS score >1
Presentation
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Site of vessel occlusion

Time of stroke symptom onset determination
  Witnessed

52.2% (338/648)

52.0% (272/523)

52.8% (38/72)

52.9% (27/51)

  Wake up

10.0% (65/648)

10.5% (55/523)

4.2% (3/72)

13.7% (7/51)

   Unwitnessed (time last seen well)

37.8% (245/648)

37.5% (196/523)

43.1% (31/72)

33.3% (17/51)

Time from onset to door, min†‡

193.0 [83.0–378.0]
(n=631)

182.0 [78.0–361.0]
(n=508)

241.0 [114.0–406.0]
(n=71)

306.0 [87.0–491.0]
(n=50)

Time from door to arterial puncture, min§

68.0 [40.0–102.0] (n=629)

68.0 [41.0–102.0] (n=507)

59.5 [37.5–92.0] (n=72)

77.5 [43.0–109.5] (n=48)

27.0 [16.0–44.0] (n=646)

28.0 [17.0–44.0] (n=521)

31.0 [19.0–47.0] (n=72)

23.0 [14.0–33.0] (n=51)

Procedure
 Time from arterial puncture to mTICI
2b–3 else final angiogram, min

(Continued )
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Continued
All subjects (N=650)

Cohort A/anterior circulation ASPECTS≥6 (n=525)

Cohort B/anterior circulation ASPECTS<6 (n=72)

Cohort C/posterior
circulation (n=51)

   Direct aspiration alone

62.9% (409/650)

63.0% (331/525)

59.7% (43/72)

64.7% (33/51)

  Direct aspiration with penumbra 3D
Revascularization Device

36.5% (237/650)

36.6% (192/525)

38.9% (28/72)

33.3% (17/51)

  Target vessel

43.4% (282/650)

43.4% (228/525)

52.8% (38/72)

31.4% (16/51)

  Distal vasculature

8.2% (53/650)

7.2% (38/525)

15.3% (11/72)

7.8% (4/51)

   Proximal stenosis or tandem lesion

2.5% (16/650)

2.1% (11/525)

6.9% (5/72)

0.0% (0/51)

   Intracranial carotid artery disease

0.6% (4/650)

0.8% (4/525)

0.0% (0/72)

0.0% (0/51)

First pass treatment modality

Additional attempts on∥

% (n/N), median [IQR], mean (SD). 3D indicates 3-dimensional; ACA, anterior cerebral artery; ASPECTS, Alberta Stroke Program Early CT Score; ICA, internal carotid
artery; ICA-T, ICA-Terminus; IQR, interquartile range; IV r-tPA, intravenous recombinant tissue-type plasminogen activator; MCA, middle cerebral artery; mRS, modified
Rankin Scale; mTICI, modified Thrombolysis in Cerebral Infarction; N/A, not applicable; NIHSS, National Institutes of Health Stroke Scale; PCA, posterior cerebral artery;
pc-ASPECTS, posterior circulation–ASPECTS; and SCA, superior cerebellar artery.
*Collected only for patients in the United States.
†Patients with onset time unknown are excluded from analysis.
‡Patients already admitted to hospital before stroke are assigned an onset to admission time of 0 min.
§Patients with prestroke admission at the hospital are excluded from the analysis.
∥Multiple responses allowed for each patient.
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from door to puncture was 68 minutes (interquartile
range, 40–102). Median ASPECTS was 8, and median
posterior circulation ASPECTS was 9.
Most patients had an anterior circulation LVO (92.2%)
and the remaining 7.8% had a posterior circulation LVO.
Two patients with anterior circulation LVO were missing
ASPECTS and, therefore, not assigned to any cohort. The
most common anterior LVO locations were the M1 middle cerebral artery (59.9%), M2 middle cerebral artery
(18.9%), and internal carotid artery terminus (13.9%).
The most common posterior LVO locations were the basilar terminus (37.3%), posterior cerebral artery (31.4%),
and middle portion of the basilar artery (17.6%).
Procedural data are available in Table 1. Frontline
treatment was aspiration alone in 62.9% of cases and
aspiration combined with the 3D Revascularization
Device in 36.5% of cases. For frontline aspiration alone
cases, the most common reperfusion catheters chosen
were the ACE68 (43.5%) and the JET7 (37.9%). For
frontline combined technique cases, the most common
reperfusion catheters chosen were the JET7 (49.4%)
and the ACE68 (26.2%). In 8 cases, the 3D Revascularization Device was used with a non-Penumbra catheter as frontline treatment. Median time from puncture to
mTICI 2b to 3 reperfusion was 26 minutes (interquartile
range, 15–40). Additional device use details and preprocedural and procedural time metrics are available in the
Data Supplement.

CI, 85.3%–90.4%]) postprocedure. Functional outcome
(mRS score 0–2) at 90 days was 55.8% (342/613
[95% CI, 51.9%–59.7%]). The Figure shows a full distribution of mRS scores at 90 days.
Vessel perforation occurred in 0.3% (2/650) of cases,
vessel dissection in 0.9% (6/650), and ENT in 2.8%
(18/650). Device-related SAE within 24 hours occurred
in 0.6% (4/650) of cases, procedure-related SAE within
24 hours in 5.8% (38/650), neurological deterioration
in 9.1% (59/650), and sICH within 24 hours in 3.8%
(25/650). Overall, 36.5% (237/650) of patients experienced any ICH within 24 hours. Using ECASS classification (Table 3), rate of PH-2 was 3.1% (20/650), and rate
of SAH was 8.2% (53/650). All-cause mortality at 90
days was 15.5% (101/650 [95% CI, 12.8%–18.3%]).

Outcomes—Cohort A (Anterior LVO With
ASPECTS≥6)

Outcome information is available in Table 2. Successful
revascularization (mTICI 2b–3) was achieved in 56.8%
(368/648) of cases postfirst pass, 76.4% (496/649)
post-Penumbra System, and 87.8% (571/650 [95%

For cohort A, mTICI 2b to 3 was achieved in 56.4%
(295/523) of cases postfirst pass, 75.2% (394/524)
post-Penumbra System, and 87.4% (459/525 [95% CI,
84.6%–90.3%]) postprocedure. At 90 days, mRS score
0 to 2 was 59.6% (295/495 [95% CI, 55.3%–63.9%]).
Vessel perforation occurred in 0.4% (2/525) of cases,
vessel dissection in 1.0% (5/525), and ENT in 2.5%
(13/525). Device-related SAE within 24 hours occurred
in 0.6% (3/525) of cases, procedure-related SAE within
24 hours in 5.1% (27/525), neurological deterioration
in 8.0% (42/525), and sICH within 24 hours in 3.8%
(20/525). Overall, 35.6% (187/525) of cohort A experienced any ICH within 24 hours. Using ECASS classification (Table 3), rate of PH-2 was 3.2% (17/525), and
rate of SAH was 9.0% (47/525). All-cause mortality at
90 days was 14.1% (74/525 [95% CI, 11.1%–17.1%]).
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Outcomes
All subjects (N=650)

Cohort A/anterior circulation
ASPECTS≥6 (n=525)

Cohort B/anterior circulation
ASPECTS<6 (n=72)

Cohort C/posterior
circulation (n=51)
72.5% (37/51)

mTICI 2b–3 postfirst pass*

56.8% (368/648)

56.4% (295/523)

47.2% (34/72)

mTICI 2c–3 postfirst pass*

41.5% (269/648)

40.5% (212/523)

33.3% (24/72)

60.8% (31/51)

mTICI 3 postfirst pass*

31.8% (206/648)

30.6% (160/523)

22.2% (16/72)

56.9% (29/51)

mTICI 2b–3 post-Penumbra
System

76.4% (496/649)

75.2% (394/524)

77.8% (56/72)

86.3% (44/51)

mTICI 2b–3 postprocedure

87.8% (571/650)
(85.3%–90.4%)

87.4% (459/525)
(84.6%–90.3%)

87.5% (63/72)
(79.9%–95.1%)

92.2% (47/51)
(84.8%–99.5%)

mTICI 2c–3 postprocedure

66.2% (430/650)

65.9% (346/525)

61.1% (44/72)

74.5% (38/51)

15.5% (101/650)
(12.8%–18.3%)

14.1% (74/525)
(11.1%–17.1%)

25.0% (18/72)
(15.0%–35.0%)

17.6% (9/51)
(7.2%–28.1%)

ENT

2.8% (18/650) (1.5%–4.0%)

2.5% (13/525) (1.1%–3.8%)

6.9% (5/72) (1.1%–12.8%)

0.0% (0/51) (0.0%–0.0%)

Neurological Deterioration

9.1% (59/650)

8.0% (42/525)

16.7% (12/72)

9.8% (5/51)

Safety outcomes
 All-cause mortality at 90
days

sICH within 24 h

3.8% (25/650) (2.4%–5.3%)

3.8% (20/525) (2.2%–5.4%)

5.6% (4/72) (0.3%–10.8%)

2.0% (1/51) (0.0%–5.8%)

Vessel perforation

0.3% (2/650) (0.0%–0.7%)

0.4% (2/525) (0.0%–0.9%)

0.0% (0/72) (0.0%–0.0%)

0.0% (0/51) (0.0%–0.0%)

Vessel dissection
 Device-related SAE, within
24 h
Device-related SAE, all
 Procedure-related SAE,
within 24 h
Procedure-related SAE, all

0.9% (6/650) (0.2%–1.7%)

1.0% (5/525) (0.1%–1.8%)

0.0% (0/72) (0.0%–0.0%)

2.0% (1/51) (0.0%–5.8%)

0.6% (4/650) (0.0%–1.2%)

0.6% (3/525) (0.0%–1.2%)

1.4% (1/72) (0.0%–4.1%)

0.0% (0/51) (0.0%–0.0%)

1.1% (7/650) (0.3%–1.9%)

0.8% (4/525) (0.0%–1.5%)

2.8% (2/72) (0.0%–6.6%)

2.0% (1/51) (0.0%–5.8%)

5.8% (38/650) (4.0%–7.6%)

5.1% (27/525) (3.3%–7.0%)

9.7% (7/72) (2.9%–16.6%)

7.8% (4/51) (0.5%–15.2%)

Downloaded from http://ahajournals.org by on April 11, 2022

7.7% (50/650) (5.6%–9.7%)

7.0% (37/525) (4.9%–9.2%)

11.1% (8/72) (3.9%–18.4%)

9.8% (5/51) (1.6%–18.0%)

 Device- or procedurerelated SAE, within 24 h

5.8% (38/650) (4.0%–7.6%)

5.1% (27/525) (3.3%–7.0%)

9.7% (7/72) (2.9%–16.6%)

7.8% (4/51) (0.5%–15.2%)

 Device- or procedurerelated SAE, all

8.0% (52/650) (5.9%–10.1%)

7.2% (38/525) (5.0%–9.5%)

11.1% (8/72) (3.9%–18.4%)

11.8% (6/51) (2.9%–20.6%)

43.8% (21/48)

mRS score 0–2 progression
Day 7–10 or discharge

41.7% (257/616)

45.2% (225/498)

14.7% (10/68)

Day 30

49.8% (308/618)

54.3% (271/499)

23.9% (16/67)

42.0% (21/50)

Day 90

55.8% (342/613)
(51.9%–59.7%)

59.6% (295/495)
(55.3%–63.9%)

32.3% (21/65)
(20.9%–43.7%)

49.0% (25/51)
(35.3%–62.7%)

NIHSS progression
At 24 h

6.0 [2.0–15.0] (n=626)

6.0 [2.0–15.0] (n=507)

15.0 [8.0–22.0] (n=69)

4.0 [1.0–10.0] (n=48)

Day 7–10 or discharge

3.0 [1.0–11.0] (n=614)

3.0 [0.0–10.0] (n=500)

12.5 [6.0–20.0] (n=68)

2.0 [0.0–4.5] (n=44)

% (n/N), % (n/N) (95% CI), median [IQR]. ASPECTS indicates Alberta Stroke Program Early CT Score; ENT, embolization in previously uninvolved or new territories;
IQR, interquartile range; mRS, modified Rankin Scale; mTICI, modified Thrombolysis in Cerebral Infarction; NIHSS, National Institutes of Health Stroke Scale; SAE, serious adverse event; and sICH, symptomatic intracranial hemorrhage.
*Two subjects vessel not examined, unable to assess.

Outcomes—Cohort B (Anterior LVO With
ASPECTS<6)
For cohort B, mTICI 2b to 3 was achieved in 47.2%
(34/72) of cases postfirst pass, 77.8% (56/72) postPenumbra System, and 87.5% (63/72 [95% CI, 79.9%–
95.1%]) postprocedure. At 90 days, mRS score 0 to 2
was 32.3% (21/65 [95% CI, 20.9%–43.7%]).
Vessel perforation occurred in 0.0% (0/72) of
cases, vessel dissection in 0.0% (0/72), and ENT in
6.9% (5/72). Device-related SAE within 24 hours
occurred in 1.4% (1/72) of cases, procedure-related
SAE within 24 hours in 9.7% (7/72), neurological deterioration in 16.7% (12/72), and sICH within
774   March 2022

24 hours in 5.6% (4/72). Overall, 54.2% (39/72) of
cohort B experienced any ICH within 24 hours. Using
ECASS classification (Table 3), rate of PH-2 was 4.2%
(3/72), and rate of SAH was 4.2% (3/72). All-cause
mortality at 90 days was 25.0% (18/72 [95% CI,
15.0%–35.0%]).

Outcomes—Cohort C (Posterior LVO)
For cohort C, mTICI 2b to 3 was achieved in 72.5%
(37/51) of cases postfirst pass, 86.3% (44/51) postPenumbra System, and 92.2% (47/51 [95% CI, 84.8%–
99.5%]) postprocedure. At 90 days, mRS score 0 to 2
was 49.0% (25/51 [95% CI, 35.3%–62.7%]).
Stroke. 2022;53:769–778. DOI: 10.1161/STROKEAHA.121.034268
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Figure. Distribution of the modified Rankin Scale (mRS) scores at 90 d for the full study population (all patients) and the prespecified cohorts (Cohort A, ASPECTS [Alberta Stroke Program Early CT Score] 6-10; cohort B, ASPECTS 0-5, large core infarct;
and cohort C, posterior circulation occlusion).
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Vessel perforation occurred in 0.0% (0/51) of cases,
vessel dissection in 2.0% (1/51), and ENT in 0.0%
(0/51). Device-related SAE within 24 hours occurred
in 0.0% (0/51) of cases, procedure-related SAE within
24 hours in 7.8% (4/51), neurological deterioration in
9.8% (5/51), and sICH within 24 hours in 2.0% (1/51).
Overall, 19.6% (10/51) of cohort C experienced any ICH
within 24 hours. Using ECASS classification (Table 3),
rate of PH-2 was 0.0% (0/51), and rate of SAH was
5.9% (3/51). All-cause mortality at 90 days was 17.6%
(9/51 [95% CI, 7.2%–28.1%]).

effect mentioned by Lin and Saver18 in their publication
regarding minimal clinically important difference for substantial reperfusion. The observed 90-day mRS score 0
to 2 success rate (59.6% [95% CI, 55.3%–63.9%]) was
better than expected (predetermined expected rate was
45% [95% CI, 40.3%–49.5%]).

Real-World COMPLETE Registry Versus
Randomized Clinical Trials

To date, COMPLETE is the largest prospective study
evaluating the real-world experience of using the Penumbra System as the frontline MT approach in patients
with LVO-AIS. In the anterior circulation LVO with
ASPECTS≥6 cohort, the study demonstrated a postprocedure revascularization success (mTICI 2b–3) rate of
87.4% and an excellent first pass effect (after a single
attempt with the Penumbra System, mTICI 2b to 3, mTICI
2c to 3, and mTICI 3 was achieved in 56.4%, 40.5%,
and 30.6% of patients, respectively). These angiographic
results translated to a high proportion of patients with
good clinical outcomes, with close to 60% of patients
regaining functional independence at 90 days. Safety
results demonstrated low rates of sICH (3.8%) and allcause mortality (14.1%). The observed postprocedure
mTICI 2b to 3 rate (87.4% [95% CI, 84.6 %–90.3%])
fell within the range of our predetermined expected rate
(85% [95% CI, 81.9%–88.1%]). The 95% CI of 84.6%
to 90.3% is consistent with the 85% to 90% target

To accurately capture real-world performance, COMPLETE
involved a large number of sites and a range of operator
of experience levels. Prior randomized clinical trials, COMPASS and ASTER, selected high-volume sites with experienced operators.13,16 In COMPASS, the rates of mTICI 2b
to 3 at end of procedure, functional independence (mRS
score 0–2), sICH, and all-cause mortality were 92%, 52%,
6%, and 22%, respectively.16 In ASTER, the rates of mTICI
2b to 3 at end of procedure, functional independence
(mRS score 0–2), sICH, and all-cause mortality were
85%, 45%, 5%, and 19%, respectively.13 As comparison,
in the anterior circulation LVO with ASPECTS≥6 cohort of
our COMPLETE real-world registry, the rates of mTICI 2b
to 3 at end of procedure, functional independence (mRS
score 0–2), sICH, and all-cause mortality were 87%, 60%,
4%, and 14%, respectively. Despite including a wide range
of clinical site and operator experience levels, the COMPLETE registry’s angiographic, functional independence,
and safety outcomes were comparable to, or better than
prior randomized trials. Additionally, both COMPASS and
ASTER restricted enrollment to patients presenting within
6 hours of symptom onset whereas COMPLETE did not
restrict by time from symptom onset.13,16
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Table 3. Intracranial Hemorrhage Within 24 Hours, ECASS Classification
Intracranial hemorrhage by ECASS
classification

All subjects (N=650)

Cohort A/anterior circulation
ASPECTS≥6 (n=525)

Cohort B/anterior circulation
ASPECTS<6 (n=72)

Cohort C/posterior circulation
(n=51)

Total intracranial hemorrhage within 24 h*

36.5% (237/650)
(32.8%–40.2%)

35.6% (187/525)
(31.5%–39.7%)

54.2% (39/72)
(42.7%–65.7%)

19.6% (10/51)
(8.7%–30.5%)

IPH

31.4% (204/650)
(27.8%–35.0%)

29.9% (157/525)
(26.0%–33.8%)

54.2% (39/72)
(42.7%–65.7%)

13.7% (7/51)
(4.3%–23.2%)

HI-1

8.5% (55/650) (6.3%–10.6%)

8.6% (45/525) (6.2%–11.0%)

9.7% (7/72) (2.9%–16.6%)

3.9% (2/51) (0.0%–9.2%)

HI-2

15.1% (98/650) (12.3%–17.8%)

13.5% (71/525) (10.6%–16.4%)

33.3% (24/72) (22.4%–44.2%)

5.9% (3/51) (0.0%–12.3%)

PH-1

5.2% (34/650) (3.5%–6.9%)

5.1% (27/525) (3.3%–7.0%)

6.9% (5/72) (1.1%–12.8%)

3.9% (2/51) (0.0%–9.2%)

PH-2

3.1% (20/650) (1.7%–4.4%)

3.2% (17/525) (1.7%–4.8%)

4.2% (3/72) (0.0%–8.8%)

0.0% (0/51) (0.0%–0.0%)

1.8% (12/650) (0.8%–2.9%)

2.1% (11/525) (0.9%–3.3%)

1.4% (1/72) (0.0%–4.1%)

0.0% (0/51) (0.0%–0.0%)

IVH
RIH

0.5% (3/650) (0.0%–1.0%)

0.4% (2/525) (0.0%–0.9%)

1.4% (1/72) (0.0%–4.1%)

0.0% (0/51) (0.0%–0.0%)

SAH

8.2% (53/650) (6.1%–10.3%)

9.0% (47/525) (6.5%–11.4%)

4.2% (3/72) (0.0%–8.8%)

5.9% (3/51) (0.0%–12.3%)

SDH

0.0% (0/650) (0.0%–0.5%)

0.0% (0/525) (0.0%–0.0%)

0.0% (0/72) (0.0%–0.0%)

0.0% (0/51) (0.0%–0.0%)

EDH

0.0% (0/650) (0.0%–0.5%)

0.0% (0/525) (0.0%–0.0%)

0.0% (0/72) (0.0%–0.0%)

0.0% (0/51) (0.0%–0.0%)

% (n/N) (95% CI). ASPECTS indicates Alberta Stroke Program Early CT Score; ECASS, European Cooperative Acute Stroke Study; EDH, epidural hematoma; HI,
hemorrhagic infarction; ICH, intracranial hemorrhage; IPH, intraparenchymal hemorrhage; IVH, intraventricular hemorrhage; PH, parenchymal hematoma; RIH, any intraparenchymal hemorrhage remote from the infarcted tissue; SAH, subarachnoid hemorrhage; and SDH, subdural hematoma.
*Multiple response is allowed.
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Several factors contributed to the excellent angiographic, functional, and safety outcomes found in our
COMPLETE registry. Technical advances over the years
have made aspiration catheters more trackable and easier to navigate. The wide availability of larger inner diameter aspiration catheters (eg, JET 7) and newer generation
pump (eg, ENGINE pump) improves the efficiency of
aspiration and may have led to the high rate of successful revascularization seen in COMPLETE. Additionally,
the functional independence rate (59.6%) is one of the
highest reported in the literature for patients with anterior circulation LVO with ASPECTS≥6 treated frontline
with Penumbra System. This can be partially explained
by the high rate of first pass successful revascularization to mTICI 2b to 3 (56.4%) and partially explained by
better patient selection. Since the series of positive MT
trials,3–8 advanced imaging to screen patients is more
prevalent,6,19 and many stroke teams have established
clear patient selection criteria for MT. These improvements potentially contributed to the higher rate of good
clinical outcome, lower rate of sICH, and lower rate of
all-cause mortality found in this study.

Additional Subgroup Outcomes in the
Complete Real-World Registry
Despite the large sample size (N=650), the current
study had few patients enrolled with anterior circulation
LVO and ASPECTS<6 (n=72), or posterior circulation
LVO (n=51). These cohorts yielded several unexpected
observations. Functional independence at 90 days was
better than expected (32.3% for low ASPECTS, and
49.0% for posterior LVO). These rates are numerically
higher than those reported by Kaesmacher et al20 in a
776   March 2022

recent multicenter pooled analysis of 237 patients with
low ASPECTS and those reported by Deb-Chatterji et
al21 in a subgroup analysis of 152 patients from the German Stroke Registry–Endovascular Treatment with low
ASPECTS. In the Kaesmacher et al20 and Deb-Chatterji
et al21 studies, functional independence was achieved
in 24.6% of patients and 21.7% of patients, respectively. Additionally, our study’s low ASPECTS cohort had
favorable rates of sICH (5.6%) and all-cause mortality
(25.0%) when compared with Kaesmacher et al20 (sICH
7.2%, all-cause mortality 40.1%) and Deb-Chatterji et
al21 (sICH not reported, all-cause mortality 44.7%).
There are limited prospective independently adjudicated data involving exclusively Penumbra System as
frontline therapy on posterior circulation LVOs. In our
cohort, we had a better than expected rate of functional
independence at 90 days (49.0%) and low rates of sICH
(2.0%) and all-cause mortality at 90 days (17.6%). This
compares favorably to a recent systematic review of posterior circulation LVO MT treatment which demonstrated
38% favorable outcomes at 90 days and 30% mortality.22
The high rate of successful revascularization achieved
in COMPLETE’s posterior circulation cohort (92.2%
mTICI 2b–3 postprocedure and first pass mTICI 2b–3,
2c–3, and 3 of 72.5%, 60.8%, and 56.9%, respectively,
versus 56.4%, 40.5%, and 30.6%, respectively, in the
anterior circulation LVO with ASPECTS≥6 cohort) is an
important finding that warrants further investigation.

Strengths and Limitations
Limitations of the COMPLETE registry include the lack
of a randomized comparison group, the ability to enroll
emergent cases after the procedure (potentially biasing
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The COMPLETE registry found that use of the Penumbra System for frontline MT treatment of patients with
LVO-AIS in a real-world setting was associated with
angiographic, clinical, and safety outcomes that were
comparable to prior randomized clinical trials that utilized
stringent site and operator selection criteria.
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